Axon to Release Third Quarter 2026 Earnings on November 5, 2026

AXON (Nasdaq: AXON), the global public safety technology leader, today announced that it will report third quarter 2026 financial results after the market closes on November 5, 2026. AXON will host a live Zoom video webinar to discuss the company's financial results at 5:00 p.m. ET that same day.

Axon is the global leader in public safety technology, relentlessly innovating to protect more lives in more places.

The live webinar to discuss financial results, followed by Q&A, will be linked from Axon's investor relations website at https://investor.axon.com. An archived replay will be available after the call ends.

Upcoming Conference Participation
The Company also announced that Axon will participate in the following upcoming conferences. If applicable, events will be webcast live and archived on Axon's investor relations website at https://investor.axon.com.

  • 2026 Deutsche Bank's Global Space and Defense Tech Summit - November 17
  • 2026 RBC Capital Markets Global TIMT Conference - November 18
  • 7th Annual Needham Virtual Tech Week - November 19
  • 2026 UBS Global Technology and AI Conference - December 2
  • Nasdaq's 55th London Investor Conference - December 9

About Axon
AXON (Nasdaq: AXON) is the global leader in public safety technology supporting state, local, federal and international public safety agencies with technology designed to Protect Life. Complementing its mission, AXON's growing Enterprise market focuses on protecting critical infrastructure and frontline workers across multiple industries including corporate security, hospitality, retail and healthcare. Founder-led since 1993, AXON builds products with transparency and responsibility. From TASER energy devices to today's connected network of hardware - including cameras, drones, and robotics - cloud software, sensors, and AI-tools, the AXON Ecosystem helps seamlessly protect people and places when it matters most. To ensure these technologies align with community expectations, AXON's independent Ethics & Equity Advisory Council guides the ethical, inclusive, and accountable design of its products and services. Learn more about the EEAC and AXON's Responsible Innovation framework at Axon Responsibility. 

Non-Axon trademarks are the property of their respective owners. Axon, Axon Ecosystem, TASER, the Delta Logo and the Axon + Delta Logo are trademarks of Axon Enterprise, Inc., some of which are registered in the US and other countries. For more information, visit www.axon.com/legal. All rights reserved.

Please visit https://investor.axon.com and https://www.axon.com/newsroom for more information.

CONTACT:
Investor Relations
Axon Enterprise, Inc.
IR@axon.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/axon-to-release-third-quarter-2026-earnings-on-november-5-2026-302917259.html

SOURCE Axon

News Provided by PR Newswire via QuoteMedia

AXON
The Conversation (0)

America Can't Make Its Own Ammunition Metal. A Nevada Project Just Defined One of the Largest Domestic Sources

Energy Metal News News Commentary - There is a metal most people have never heard of that the U.S. military cannot do without and cannot currently produce at home. It hardens the lead in ammunition, it is essential to the primers that make bullets fire, and it goes into flame retardants,... Keep Reading...
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs) No approved MS DMTs have shown... Keep Reading...
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding sharesAwakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics... Keep Reading...
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, today is reporting its financial results and business highlights for the three and nine months ended... Keep Reading...
Awakn Life Sciences Signs MOU with NHS  and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Awakn Life Sciences Signs MOU with NHS and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase IIIAwakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and... Keep Reading...

Interactive Chart

Latest Press Releases

Related News